American CryoStem Corporation (OTC: CRYO), a clinical stage biotechnology Company, global licensor and a pioneer in autologous cellular processing and therapies announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) authorized by published code 15 U.S.C. 3710a of US Title 15 Commerce and Trade. (https://www.disa.mil/about/cto/crada-process-overview) The Collaborative work will be conducted at the Biomedical Research Laboratory in Bethesda, Maryland.

American CryoStem Corporation Issues Shareholder LetterEATONTOWN, NJ / ACCESSWIRE / September 23, 2020 / American CryoStem Corporation (OTC PINK:CRYO) is a clinical stage biotechnology company, global licensor, […]

American CryoStem Corporation Issues Shareholder LetterThe debt issuance has been executed in accordance with the terms of the Debenture contained in the Company\’s 10-Q through the […]

American CryoStem Corporation Issues Shareholder LetterEATONTOWN, NJ / ACCESSWIRE / December 5, 2019 / American CryoStem Corporation (OTC PINK: CRYO) a leading strategic developer, marketer, and global […]

The Company and the Principal Investigator announce the addition of sub-investigators to the clinical trial team with extensive experience assessing and treating athletes and military personnel […]

ATCell™ Expanded Autologous, Adipose-Derived Mesenchymal Stem Cells Deployed via Intravenous Infusion for the Treatment of Post Concussion Syndrome (PCS) in Retired Military and Athletes EATONTOWN, NJ […]